These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 4019692)

  • 1. Quantitative analysis of vigabatrin in plasma and urine by reversed-phase high-performance liquid chromatography.
    Smithers JA; Lang JF; Okerholm RA
    J Chromatogr; 1985 May; 341(1):232-8. PubMed ID: 4019692
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor.
    Gibson JP; Yarrington JT; Loudy DE; Gerbig CG; Hurst GH; Newberne JW
    Toxicol Pathol; 1990; 18(2):225-38. PubMed ID: 2399411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor.
    Yarrington JT; Gibson JP; Dillberger JE; Hurst G; Lippert B; Sussman NM; Heydorn WE; Marler RJ
    Toxicol Pathol; 1993; 21(5):480-9. PubMed ID: 8115824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer.
    Haegele KD; Schechter PJ
    Clin Pharmacol Ther; 1986 Nov; 40(5):581-6. PubMed ID: 3769388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vigabatrin--interference with urinary amino acid analysis.
    Preece MA; Sewell IJ; Taylor JA; Green A
    Clin Chim Acta; 1993 Sep; 218(1):113-6. PubMed ID: 8299214
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical pharmacology of vigabatrin.
    Schechter PJ
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):19S-22S. PubMed ID: 2667604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of vigabatrin in plasma by reversed-phase high-performance liquid chromatography.
    Tsanaclis LM; Wicks J; Williams J; Richens A
    Ther Drug Monit; 1991 May; 13(3):251-3. PubMed ID: 1926280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of single and multiple increasing doses of vigabatrin on brain GABA metabolism and correlation with vigabatrin plasma concentration.
    Valdizán EM; Armijo JA
    Biochem Pharmacol; 1992 May; 43(10):2143-50. PubMed ID: 1599502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute encephalopathy with vigabatrin.
    Sharief MK; Sander JW; Shorvon SD
    Lancet; 1993 Sep; 342(8871):619. PubMed ID: 8102747
    [No Abstract]   [Full Text] [Related]  

  • 10. Vigabatrin and urinary 5-oxoproline.
    Meister A
    Lancet; 1989 Nov; 2(8673):1216. PubMed ID: 2572924
    [No Abstract]   [Full Text] [Related]  

  • 11. Vigabatrin and behaviour disturbances.
    Sander JW; Hart YM
    Lancet; 1990 Jan; 335(8680):57. PubMed ID: 1967367
    [No Abstract]   [Full Text] [Related]  

  • 12. Vigabatrin.
    Lancet; 1989 Mar; 1(8637):532-3. PubMed ID: 2564063
    [No Abstract]   [Full Text] [Related]  

  • 13. Bipolar affective psychosis after vigabatrin.
    Naumann M; Supprian T; Kornhuber J; Lange KW; Reiners K
    Lancet; 1994 Mar; 343(8897):606-7. PubMed ID: 7906364
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute effects of gamma-vinyl GABA on the GABAergic system in rats as studied by microdialysis.
    Jolkkonen J; Mazurkiewicz M; Lahtinen H; Riekkinen P
    Eur J Pharmacol; 1992 Dec; 229(2-3):269-72. PubMed ID: 1490526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assay of gamma-vinyl-gamma-aminobutyric acid (4-amino-hex-5-enoic acid) in plasma and urine by automatic amino acid analysis. Application to human pharmacokinetics.
    Grove J; Alken RG; Schechter PJ
    J Chromatogr; 1984 Mar; 306():383-7. PubMed ID: 6715477
    [No Abstract]   [Full Text] [Related]  

  • 16. Further evaluation of Vigabatrin therapy in 4-hydroxybutyric aciduria.
    Jakobs C; Michael T; Jaeger E; Jaeken J; Gibson KM
    Eur J Pediatr; 1992 Jun; 151(6):466. PubMed ID: 1628679
    [No Abstract]   [Full Text] [Related]  

  • 17. Stoichiometry and stability of the adduct formed between human 4-aminobutyrate aminotransferase and 4-aminohex-5-enoate: sequence of a labelled peptide.
    De Biase D; Bolton JB; Barra D; Bossa F; John RA
    Biochimie; 1989 Apr; 71(4):491-5. PubMed ID: 2503053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute encephalopathy with vigabatrin.
    Sälke-Kellermann A; Baier H; Rambeck B; Boenigk HE; Wolf P
    Lancet; 1993 Jul; 342(8864):185. PubMed ID: 8101289
    [No Abstract]   [Full Text] [Related]  

  • 19. Vigabatrin for startle-disease with altered cerebrospinal-fluid free gamma-aminobutyric acid.
    Stephenson JB
    Lancet; 1992 Aug; 340(8816):430-1. PubMed ID: 1353584
    [No Abstract]   [Full Text] [Related]  

  • 20. Gamma-allenyl GABA, a new inhibitor of 4-amino butyrate amino transferase. Comparison with other inhibitors of this enzyme.
    Jung MJ; Heydt JG; Casara P
    Biochem Pharmacol; 1984 Nov; 33(22):3717-20. PubMed ID: 6508828
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.